Atossa Therapeutics (ATOS) Price & Analysis

Compare

2,540 Followers

ATOS Stock Chart & Stats

$4.99

>-$0.01(-0.49%)

At close: Jan 08 4:00 PM EST

$4.99

>-$0.01(-0.49%)

Day’s Range― - ―

52-Week Range$4.78 - $19.33

Previous CloseN/A

Volume314.80K

Average Volume (3M)1.16M

Market Cap

$42.97M

Enterprise Value-$8.87M

Total Cash (Recent Filing)$51.84M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta2.15

Next Earnings

Apr 01, 2026

EPS Estimate

-1.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding8,611,428

10 Day Avg. Volume1,949,046

30 Day Avg. Volume1,157,820

Financial Highlights & Ratios

PEG Ratio0.28

Price to Book (P/B)1.66

Price to Sales (P/S)0.00

P/FCF Ratio-5.64

Enterprise Value/Market Cap-0.21

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit554.63

Enterprise Value/Ebitda0.27

Forecast

1Y Price Target

$18.33

Price Target Upside267.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase 2 data showing a clear progression-free survival advantage and a favorable safety profile for Z-endoxifen versus tamoxifen support potential adoption in ER-positive metastatic breast cancer.

Development StrategySubmission of an investigational new drug application for Z-endoxifen, selection of a global contract research organization for dose-ranging studies, and amended trial designs intended to accelerate readouts establish clear operational catalysts ahead.

Regulatory IncentivesFDA Rare Pediatric Disease designation for endoxifen in Duchenne muscular dystrophy could make the therapy eligible for a Priority Review Voucher if approved, creating a significant commercial and strategic incentive.

Bears Say

Development Timeline RiskPotential need to secure additional financing could force reprioritization or delays in clinical programs if access to capital is constrained, slowing development timelines.

Financing RiskSignificant share price decline and market expectations of a dilutive capital raise create material downside risk through potential equity dilution and investor concern.

Market VolatilityShare volatility and limited trading liquidity could amplify negative reactions to clinical or regulatory setbacks, increasing downside pressure on the stock.

Atossa Therapeutics News

Atossa Therapeutics price target lowered to $10 from $35 at Craig-Hallum

Craig-Hallum lowered the firm’s price target on Atossa Therapeutics (ATOS) to $10 from $35 and keeps a Buy...

4h ago

ATOS

Upcoming Stock Splits This Week (February 2 to February 6) – Stay Invested

These are the upcoming stock splits for the week of February 2 to February 6, based on TipRanks’ Stock...

11d ago

PBM

AREB

Atossa Genetics trading halted, news pending

19:50 EST Atossa Genetics trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

13d ago

ATOS

Atossa Therapeutics: FDA grants orphan designation to (Z)-endoxifen

Atossa Therapeutics (ATOS) announced that the U.S. FDA Office of Orphan Products Development has granted Orphan Drug Designation...

27d ago

ATOS

FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen

Atossa Therapeutics (ATOS)’ (Z)-endoxifen was granted FDA orphan designation as a treatment of Duchenne muscular dystrophy, according to...

28d ago

ATOS

Atossa Therapeutics Issues 2026 Outlook and Strategic Update

Atossa Therapeutics ( ($ATOS) ) has shared an update. On February 11, 2026, Atossa Therapeutics issued a shareholder...

1d ago

ATOS

Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Therapeutics on February 5 and set a...

3d ago

ATOS

Atossa Therapeutics Sets 15-for-1 Reverse Stock Split

Atossa Therapeutics ( ($ATOS) ) has shared an announcement. On December 19, 2025, Atossa Therapeutics stockholders approved an...

17d ago

ATOS

Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program

The latest announcement is out from Atossa Therapeutics ( ($ATOS) ). In a recent Form 8-K, Atossa Therapeutics...

1M ago

ATOS

Atossa Wins FDA Clearance to Advance (Z)-Endoxifen Trial

Atossa Therapeutics ( ($ATOS) ) has issued an update. On January 6, 2026, Atossa Therapeutics announced that the...

1M ago

ATOS

Atossa Therapeutics receives “Study May Proceed” letter for breast cancer study

Atossa Therapeutics (ATOS) announced that the U.S. FDA issued a “Study May Proceed” letter for the company’s study...

1M ago

ATOS

Atossa Therapeutics: Buy Rating on Promising DMD Advancements and Strategic Growth Potential

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Atossa Therapeutics, retaining the price target of...

2M ago

ATOS

Promising Clinical Trial Results of Z-endoxifen Support Buy Rating for Atossa Therapeutics

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Atossa Therapeutics, retaining the price target of...

2M ago

ATOS

Atossa Therapeutics presents four trial updates on Z-endoxifen

Atossa Therapeutics (ATOS) presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium, SABCS,...

2M ago

ATOS

ATOS FAQ

What was Atossa Therapeutics’s price range in the past 12 months?

Atossa Therapeutics lowest stock price was $4.78 and its highest was $19.33 in the past 12 months.

What is Atossa Therapeutics’s market cap?

Atossa Therapeutics’s market cap is $42.97M.

When is Atossa Therapeutics’s upcoming earnings report date?

Atossa Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 48 days.

How were Atossa Therapeutics’s earnings last quarter?

Atossa Therapeutics released its earnings results on Nov 12, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.975 by -$0.075.

Is Atossa Therapeutics overvalued?

According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atossa Therapeutics pay dividends?

Atossa Therapeutics does not currently pay dividends.

What is Atossa Therapeutics’s EPS estimate?

Atossa Therapeutics’s EPS estimate is -1.14.

How many shares outstanding does Atossa Therapeutics have?

Atossa Therapeutics has 8,611,428 shares outstanding.

What happened to Atossa Therapeutics’s price movement after its last earnings report?

Atossa Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.975. Following the earnings report the stock price went down -1.74%.

Which hedge fund is a major shareholder of Atossa Therapeutics?

Currently, no hedge funds are holding shares in ATOS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atossa Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-48.89%

Trailing 12-Months

Asset Growth

-24.86%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atossa Therapeutics

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Atossa Therapeutics (ATOS) Earnings & Revenues

Historic Earnings Reports

ATOS Stock 12 Month Forecast

Average Price Target

$18.33

▲(267.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","41":"$41","13.25":"$13.25","22.5":"$22.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,13.25,22.5,31.75,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.59,8.236923076923077,10.883846153846154,13.530769230769229,16.177692307692304,18.824615384615385,21.471538461538458,24.118461538461535,26.765384615384612,29.41230769230769,32.059230769230766,34.70615384615384,37.35307692307691,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.59,6.569999999999999,7.55,8.53,9.51,10.489999999999998,11.469999999999999,12.45,13.43,14.409999999999998,15.389999999999999,16.369999999999997,17.349999999999998,{"y":18.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.59,5.6984615384615385,5.806923076923077,5.915384615384616,6.023846153846153,6.132307692307692,6.240769230769231,6.349230769230769,6.457692307692308,6.5661538461538465,6.674615384615384,6.783076923076923,6.891538461538461,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.161,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.485,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.765,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.644,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.002,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.363,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.345,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.443,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.743,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.344,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.849,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.59,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >